185 related articles for article (PubMed ID: 17315755)
1. [Placebo effect in Parkinson's disease].
Miwa H
No To Shinkei; 2007 Feb; 59(2):139-46. PubMed ID: 17315755
[TBL] [Abstract][Full Text] [Related]
2. [Placebo effect in Parkinson's disease].
Miwa H
Brain Nerve; 2007 Feb; 59(2):139-46. PubMed ID: 17380778
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
4. Great expectations: the placebo effect in Parkinson's disease.
Lidstone SC
Handb Exp Pharmacol; 2014; 225():139-47. PubMed ID: 25304530
[TBL] [Abstract][Full Text] [Related]
5. Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation.
Keitel A; Wojtecki L; Hirschmann J; Hartmann CJ; Ferrea S; Südmeyer M; Schnitzler A
Behav Brain Res; 2013 Aug; 250():199-205. PubMed ID: 23651878
[TBL] [Abstract][Full Text] [Related]
6. Effects of expectation on placebo-induced dopamine release in Parkinson disease.
Lidstone SC; Schulzer M; Dinelle K; Mak E; Sossi V; Ruth TJ; de la Fuente-Fernández R; Phillips AG; Stoessl AJ
Arch Gen Psychiatry; 2010 Aug; 67(8):857-65. PubMed ID: 20679593
[TBL] [Abstract][Full Text] [Related]
7. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
Quattrone A; Barbagallo G; Cerasa A; Stoessl AJ
Mov Disord; 2018 Aug; 33(8):1213-1227. PubMed ID: 30230624
[TBL] [Abstract][Full Text] [Related]
8. The placebo-reward hypothesis: dopamine and the placebo effect.
de la Fuente-Fernández R
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S72-4. PubMed ID: 20083013
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients.
Frisaldi E; Carlino E; Lanotte M; Lopiano L; Benedetti F
Cortex; 2014 Nov; 60():3-9. PubMed ID: 24457096
[TBL] [Abstract][Full Text] [Related]
10. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
[TBL] [Abstract][Full Text] [Related]
11. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation.
Mercado R; Constantoyannis C; Mandat T; Kumar A; Schulzer M; Stoessl AJ; Honey CR
Mov Disord; 2006 Sep; 21(9):1457-61. PubMed ID: 16721750
[TBL] [Abstract][Full Text] [Related]
12. Mechanism(s) of deep brain stimulation and insights into cognitive outcomes in Parkinson's disease.
Naskar S; Sood SK; Goyal V; Dhara M
Brain Res Rev; 2010 Oct; 65(1):1-13. PubMed ID: 20457181
[TBL] [Abstract][Full Text] [Related]
13. Placebo mechanisms and reward circuitry: clues from Parkinson's disease.
de la Fuente-Fernández R; Schulzer M; Stoessl AJ
Biol Psychiatry; 2004 Jul; 56(2):67-71. PubMed ID: 15231437
[TBL] [Abstract][Full Text] [Related]
14. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
[TBL] [Abstract][Full Text] [Related]
15. Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation.
Ray NJ; Jenkinson N; Wang S; Holland P; Brittain JS; Joint C; Stein JF; Aziz T
Exp Neurol; 2008 Sep; 213(1):108-13. PubMed ID: 18619592
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation].
Fehér G; Balás I; Komoly S; Dóczi T; Janszky J; Aschermann Z; Balázs E; Nagy F; Kovács N
Ideggyogy Sz; 2010 Sep; 63(9-10):314-9. PubMed ID: 21033420
[TBL] [Abstract][Full Text] [Related]
17. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease.
Bandini F; Primavera A; Pizzorno M; Cocito L
Parkinsonism Relat Disord; 2007 Aug; 13(6):369-71. PubMed ID: 17049455
[TBL] [Abstract][Full Text] [Related]
18. An update on the treatment of Parkinson's disease.
Jankovic J
Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274
[TBL] [Abstract][Full Text] [Related]
19. Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
Robert G; Drapier D; Verin M; Millet B; Azulay JP; Blin O
Mov Disord; 2009 Dec; 24(16):2316-27. PubMed ID: 19908312
[TBL] [Abstract][Full Text] [Related]
20. Long term high frequency stimulation of STN increases dopamine in the corpus striatum of hemiparkinsonian rhesus monkey.
Zhao XD; Cao YQ; Liu HH; Li FQ; You BM; Zhou XP
Brain Res; 2009 Aug; 1286():230-8. PubMed ID: 19563788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
